Loading…
← CockpitCompetitor Analysis › 1276.HK Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class HOpen in the cockpit ↗

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H1276.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

China's largest pharmaceutical R&D company, developing innovative oncology, metabolic and other prescription drugs.

≈ China's leading innovative-drug company, akin to a domestic Merck/BMS in R&D scaleMomentum neutral 41
Mkt cap
$44.9B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$26.9M
20-day average traded
Fwd P/E
28.1×
forward earnings
ROIC−WACC
+24.8 pp
WACC 7.3%
Hurdle
+7 pp
Req g minus delivered
Next earnings
152 days
19 Apr 2027
Close · HKDHK$46.58
1D-2.3%
1W-7.3%
1M-5.9%
3M-15.2%
6M-24.3%
YTD-34.6%
1Y-34.6%
ATR %4.2%
52w lowhigh42.5% off high

What Jiangsu Hengrui Pharmaceuticals does

China's largest pharmaceutical R&D company, developing innovative oncology, metabolic and other prescription drugs.

Earns mostly from selling prescription drugs to Chinese hospitals, where older drugs face government bulk-purchase tenders and newer innovative medicines carry better prices. Licensing deals with overseas drugmakers bring upfront and milestone payments. It listed in Hong Kong in 2025 on top of its Shanghai listing.

In one line: China's leading innovative-drug company, akin to a domestic Merck/BMS in R&D scale.

Products and services

  • Oncology drugs
  • Metabolic/GLP-1 drugs
  • Generic/legacy drugs
  • Out-licensed pipeline assets

Customers

  • Hospitals and oncology/specialty clinics
  • Global pharma licensing partners

Where it sits in the supply chain

  • Healthcare
  • Pharmaceuticals
  • Innovative drug R&D, manufacturing…

What could go right

  • Global out-licensing deal income
  • New drug approvals/reimbursement inclusion

What could go wrong

  • China drug-price volume-based procurement
  • Pipeline/clinical-trial failure risk

Moat: narrow (IP / patents, scale, process know-how). Largest domestic R&D pipeline and patent estate among Chinese pharma companies.

Headquarters: Lianyungang, China · Founded: 1970 · Employees: 20,602

Named competitors

Jiangsu Hengrui Pharmaceuticals at a glance

Size Jiangsu Hengrui Pharmaceuticals (1276.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $44.9B, the 37th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$46.58 on 18 Nov 2026.

Performance Over six months the shares fell 24.3%, against +16.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 11.3% over the last twelve months (peer median +14.0%); the operating margin is 27.5% (peer median 19.0%).

Valuation It trades at 28.1× forward earnings against a peer median of 19.0× (6th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 24.8 points above its cost of capital (7.3% WACC).

Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 1151276.HK 76
Six months, rebased to 100: Jiangsu Hengrui Pharmaceuticals against the median of its 20 peers (local-currency closes).

Jiangsu Hengrui Pharmaceuticals financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$37.3BHK$34.1BHK$30.1BHK$25.0BHK$24.6B
Revenue growth—+13%+20%+2%—
Gross profitHK$32.8BHK$28.9BHK$25.6BHK$20.7BHK$20.2B
EBITDAn/aHK$9.72BHK$7.88BHK$5.42BHK$4.25B
Net incomeHK$10.1BHK$8.36BHK$6.87BHK$4.75BHK$4.54B
Free cash flowHK$7.08BHK$9.03BHK$5.97BHK$6.91B-HK$652M
Capital expenditureHK$4.48BHK$3.21BHK$2.14BHK$1.64BHK$2.32B
Total debtHK$493MHK$1.04BHK$712MHK$693MHK$1.91B

Quarterly statements and history in the cockpit →

Jiangsu Hengrui Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+10%+20%688235SUNPHARMASDZ4578HLNRPRXGALDBIIBZTSBAYN235945034568DIVISLAB4502MRKROIV4519INSM36921276.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Hengrui Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%+40%20×40×60×688235SUNPHARMASDZ4578HLNRPRXGALDBIIBZTS235945034568DIVISLAB4502451936921276.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Hengrui Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%688235SUNPHARMASDZ4578HLNRPRXGALDZTS23594503DIVISLAB36921276.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiangsu Hengrui Pharmaceuticals is the large dot.

Jiangsu Hengrui Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (1276.HK vs 1801.HK vs 688235.SS vs 1177.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Jiangsu Hengrui Pharmaceuticals 1276.HK$44.9B-24%+11%27%28.1×9.1%
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
BeOne Medicines 688235.SS$45.5B+9%+25%18%59.7×19.1%
Sbp 1177.HK$12.2B+5%+15%30%17.5×-5.7%
Merck & MRK$340B+23%+5%18%16.4×8.3%

How Jiangsu Hengrui Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Hengrui Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure1276.HKPeer medianRank in peer set
1-month return-5.9%+7.0%2nd lowest of 21
6-month return-24.3%+16.9%lowest of 21
Distance from 52-week high-42.5%-7.6%2nd lowest of 21
Revenue growth (TTM)+11.3%+14.0%10th lowest of 21
Operating margin27.5%19.0%7th highest of 21
Forward P/E28.1×19.0×6th most expensive of 19
Growth the price implies (Req g, 7 yrs)9.1%7.6%7th most demanding of 18
Growth delivered (Del g)+2.0%+8.9%3rd lowest of 18
Hurdle (Req g minus delivered)+7.1 pp-2.9 pp6th most demanding of 18
ROIC minus cost of capital+24.8 pp+4.4 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiangsu Hengrui Pharmaceuticals 1276.HKHong Kong$44.9B-24%+11%27%28.1×9.1%+2.0%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Wuxi Apptec 2359.HKHong Kong$64.1B+51%+38%44%19.5×8.4%+20.4%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%

Questions

Who are Jiangsu Hengrui Pharmaceuticals's main competitors?
Named competitors: Innovent Biologics (1801.HK), BeiGene (688235.SS), Sino Biopharmaceutical (1177.HK), Merck & Co (MRK). The cockpit's measured peer set (industry) also includes BeOne Medicines (688235.SS), Sun Pharmaceutical Industries (SUNPHARMA.NS), Sandoz (SDZ.SW), Otsuka Hldgs (4578.T), Haleon (HLN.L), Royalty Pharma (RPRX).
Is Jiangsu Hengrui Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 28.1× against a peer median of 19.0×, 6th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jiangsu Hengrui Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -24.3% against +16.9% for the median peer; over one year -34.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.